文献速递胸部CT

囊性纤维化患者接受elexacaftor-tezacaftor-ivacaftor治疗后的胸部计算机断层扫描改善:早期报告

Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.
PubMed 文献 · Eur J Radiol · 2022-06-23

该回顾性、观察性、单中心研究纳入12例接受elexacaftor-tezacaftor-ivacaftor(ETI)治疗的成人囊性纤维化患者,比较治疗前与治疗至少一年后的胸部CT。治疗一年后Brody-II评分下降(-18 ± 16,p = 0.002),主要归因于黏液栓评分(-7 ± 4,p < 0.001)和支气管周围增厚评分(-9 ± 10,p = 0.002)降低,且ΔFEV1与Δ total BSII强相关(r = 0.88,p < 0.001)。

要点

  • ETI治疗一年后胸部CT Brody-II评分下降(-18 ± 16,p = 0.002)。
  • 评分下降主要来自黏液栓(-7 ± 4,p < 0.001)和支气管周围增厚(-9 ± 10,p = 0.002)。
  • ΔFEV1与Δ total BSII强相关(r = 0.88,p < 0.001)。

核心结论

  • ETI治疗一年后肺部及鼻窦形态学异常均减少。

研究设计与样本

  • 回顾性、观察性、单中心研究,2018年至2021年纳入12例接受ETI治疗的成人囊性纤维化患者,由两名对治疗不知情的经验丰富放射科医生测量Brody-II评分,并比较鼻窦CT及临床和功能数据。

关键影像表现/征象

  • 治疗一年后Brody-II评分下降(-18 ± 16,p = 0.002)。
  • 黏液栓评分下降(-7 ± 4,p < 0.001),支气管周围增厚评分下降(-9 ± 10,p = 0.002)。
  • 支气管、肺实质及过度充气评分无变化。
  • 鼻窦CT评分随ETI治疗显著改善。

诊断标准与关键数值

  • Brody-II评分观察者间可重复性满意(组内相关系数 = 0.83,95%CI 0.57-0.91)。
  • ΔFEV1与Δ total BSII强相关(r = 0.88,p < 0.001)。

临床应用与阅片要点

  • 临床和功能参数显著改善,但总肺容量除外。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have revolutionised the treatment of cystic fibrosis (CF). Chest computed tomography (CT) is key in the diagnosis and follow-up of anatomical damage to the lungs. Our study aimed to evaluate changes on lung CT scans of patients with CF after receiving elexacaftor-tezacaftor-ivacaftor (ETI) therapy for one year.

MATERIALS AND METHODS: We conducted a retrospective, observational, single-centre study between 2018 and 2021 on adult patients with CF administered ETI. We reviewed chest CT scans before and at least one year after starting ETI. The Brody-II score (BSII) was measured by two experienced radiologists who were blinded to the treatment. Paranasal sinus CT scans and clinical and functional data were also compared. Wilcoxon tests were used to compare differences, and Spearman's correlation coefficient was used to evaluate changes in forced expiratory volume in one second (FEV1) and total BSII.

RESULTS: In the period, 63 patients were given ETI, and 12 met the criteria for analysis. The inter-observer reproducibility of BSII was satisfactory (intraclass correlation coefficient = 0.83, 95% confidence interval 0.57-0.91). The BSII decreased after one year of treatment (-18 ± 16, p = 0.002) due to lower mucous plugging (-7 ± 4, p < 0.001) and peribronchial thickening (-9 ± 10, p = 0.002) scores. Bronchial, parenchymal, and hyperinflation scores were unchanged. Clinical and functional parameters were significantly improved, except for total lung capacity. The correlation between ΔFEV1 and Δtotal BSII was strong (r = 0.88, p < 0.001). The paranasal sinus CT score significantly improved with ETI treatment.

CONCLUSIONS: ETI decreased pulmonary and sinus morphological abnormalities after one year of treatment.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Bec, Reynaud-Gaubert, Arnaud, et al. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report. Eur J Radiol. 2022. PMID: 35772339. doi:10.1016/j.ejrad.2022.110421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。